Experts still favor metastasis directed therapy for oligometastatic #prostatecancer although enrollment in clinical trials is encouraged.

Thanks tombal for the shout out to the oligoPresto trial (part of PEACE 6) that is now 460/550 pts accrued.

⚡️ NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

#BladderCancer #Immunology Markus Eckstein
Journal of Clinical Oncology

ascopubs.org/doi/10.1200/JC…

Please join us during #ESTRO24 where the STORM consortium will provide the first oncological results for nodal recurrences. Thomas Zilli

• Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?- Pierre Blanchard, MD

Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala

On the train in a trial though 😉. Thunder trial started recruitment in December 23 and 40 patients recruited in only 3-4 months.

Check out the Cheat Sheet on the treatment of #ErectileDysfunction . The management algorithm outlines modifiable factors and current therapies for successful treatment. While ED can't always be cured, effective management is possible.

#EAUguidelines

uroweb.org/guidelines/sex…

How to manage patients with PSA persistence following radical prostatectomy? Presentation by Derya Tilki, MD Martini-Klinik am UKE. #APCCC24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/49Q5p3z Advanced Prostate Cancer Consensus Conference

🩺 On European Urology - Oligometastatic Bladder Cancer: Defining a Novel Entity

#BladderCancer Chris Labaki Toni Choueiri, MD Eddy Saad joaquim bellmunt

europeanurology.com/article/S0302-…

How to manage patients with PSA persistence following radical prostatectomy? Fantastic insights from Derya Tilki, MD at #Apccc24
⭕️ Risk stratification according to pathologic features, PSA levels/kinetics, and genomic classifier may aid in personalization of treatment.
Advanced Prostate Cancer Consensus Conference…

•In pts who receive salvage RT
for BCR, who needs additional systemic therapy?-Daniel E Spratt

Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala

#Metoo Hôpital : l’heure du changement a-t-elle vraiment sonné ? – Blog du Dr Géraldine Pignot …raldinepignot.lequotidiendumedecin.fr/metoo-hopital-…

Paul Sargos Vedang Murthy Sean Collins Prostate SBRT@Georgetown University GETUG Association Française d'Urologie - AFU Paul Nguyen Ploussard Guillaume Morgan Roupret ESTRO ASTRO European Association of Urology (EAU) SFRO I've used 0.2 for a number of years as a predictor - shifted to 0.1 post-icecap. My figures are ~92% reach 0.2 6 months post and ~85% reach 0.1. So it clearly parses cohort into reasonable blocks to explore de-escalation / escalation approaches from my perspective.

Sean Collins Prostate SBRT@Georgetown University May I ask why LHRHa plus Bical in the std arm. Is that your SOC?

📢⭐️Exploratory analyses of ARASENS compare undetectable PSA (<0.2 ng/ml) and time to PSA progression (≥25% relative and ≥2 ng/ml absolute increase from nadir) between groups.
✅In the overall population, 67% of patients on darolutamide achieved undetectable PSA versus 29% on…

Subset of intermediate risk in ProtecT did objectively worse with active monitoring than definitive tx.

Klotz AS series for GG2 and especially 3 had poor outcomes.

Must be clear many intermediate AS series are very low volume, usually very low percent pattern 4, and many get…

Replay: Les trois Knockdowns de Ryan Garcia sur Devin Haney

Safety of elective pelvic nodal RT on long term follow up in the POP-RT trial Priyamvada Maitre Vedang Murthy TMC Radiation Oncology ACTREC-TMC Tata Memorial Hospital. Read now in the #RedJournal . bit.ly/murthy3

That’s the point Piet Ost .
That’s why a trial is needed!
Paul Sargos GETUG

One of many sessions showing #AUA24 endorsing this non EBM treatment to the point they discuss focal as something to add to your armamentarium rather than get evidence to support its use, FDA approval, payer and guideline support, and most importantly, patient benefit.

Come on…

KEYNOTE-564 1-yr adjuvant pembro OS data hitting in NEJM today

Congrats Toni Choueiri, MD et al

Huge for the field and our high-risk localized RCC patients!

UroToday.com Georgia Cancer Center

nejm.org/doi/full/10.10…